Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PTCT
PTCT logo

PTCT News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

PTCT News

PTC Therapeutics Stock Upgraded by Jefferies Amid Positive Outlook

6d agoseekingalpha

Healthcare Stocks Decline Late Friday Afternoon

May 08 2026Yahoo Finance

PTC Therapeutics Raises Full-Year Outlook Amid Strong Sephience Launch

May 08 2026seekingalpha

PTC Therapeutics Reports Record Q1 2026 Earnings with Raised Guidance

May 08 2026seekingalpha

PTC Therapeutics Reveals Long-Term Results for Votoplam in Huntington's Disease

Apr 28 2026NASDAQ.COM

PTC and Novartis Advance Huntington's Disease Research with Votoplam

Apr 28 2026PRnewswire

PTC and Novartis Announce Votoplam Study Progress

Apr 28 2026Newsfilter

PTC Therapeutics Approves Stock Options and RSUs for New Hire

Apr 17 2026PRnewswire

PTCT Events

06/02 09:50
FDA Issues Draft Guidance for Gene Therapies
The U.S. Food and Drug Administration said it has issued draft guidance to help developers bring promising gene therapies to patients more efficiently by making greater use of existing scientific and regulatory knowledge. When finalized, the guidance will outline how sponsors can use publicly available information and established platform knowledge, including chemistry, manufacturing and controls data, nonclinical study results and clinical information, to streamline regulatory submissions for human gene therapy products that use genome editing in human somatic cells. "Today's action reflects the FDA's commitment to get safe and effective cell and gene therapies to patients faster, particularly those living with rare and life-threatening diseases who have few or no other treatment options," said Karim Mikhail, B. Pharm., M.S., Acting Director of the Center for Biologics Evaluation and Research. "By providing information on how companies may build on what is already known we are accelerating innovation without compromising the rigorous scientific standards that patients and the public depend on.Ultimately, this is about making sure that the promise of gene therapy reaches the patients who need it most, as quickly and safely as possible." This draft guidance supports the development of a wide range of cell and gene therapy products, including those that use genome editing, and is part of a broader set of complementary FDA actions in this area. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Biotech stocks include Replimune (REPL), Moderna (MRNA), Sarepta (SRPT), Xencor (XNCR), PTC Therapeutics (PTCT), Biohaven (BHVN), Edgewise Therapeutics (EWTX), Design Therapeutics (DSGN), Ultragenyx (RARE), Dyne Therapeutics (DYN), Wave Life Sciences (WVE), MeiraGTx (MGTX), uniQure (QURE), Regenxbio (RGNX), Novavax (NVAX) and Lexeo Therapeutics (LXEO).
05/12 16:20
Major Averages Finish Mixed as Semiconductor Stocks Pull Back
The major averages had a mixed finish as semiconductor stocks pulled back following a massive multi-week run. AI-driven enthusiasm pushed the S&P 500 and Nasdaq to fresh records yesterday, but investors are now confronting a harder macro backdrop than previously anticipated. Meanwhile, crude is back above $100 as hopes for a durable U.S.-Iran ceasefire continue to deteriorate, with President Trump describing negotiations as being "on life support." Of note, the Iranian Fars news service reportedly said that Iran will not join the next round of U.S. talks without five preconditions being met.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:eBay'sboard rejected GameStop'sUnder Armourreported mostly in-line Q4 results andActivist investor Nelson Peltz's Trian Fund Management is seeking investor backing for a bid to take Wendy'sprivate,BuzzFeedannounced a proposed majority investment byFDA Commissioner Marty Makary has, according to multiple media reports citing administration officials2. WALL STREET CALLS:Lowe'sto Buy at CitiAutodeskat Buy from Neutral at BofARothschildToaston risk from DoorDashU.S. rolloutZoomInfoto Underweight at Piper Sandler and to Neutral-equivalent ratings and several other firmsWall Streetof drone-maker Aevexafter its recent IPO3. AROUND THE WEB:Microsofthas already earned back more than double the capital it invested in OpenAI in terms of new revenue from services related to OpenAI, The Information reportsGoogleand Elon Musk's SpaceX are in talks for a rocket launch deal amid efforts to put orbital data centers in space, WSJ saysAlphabet'sYouTube is looking to connect creators with sponsors to secure funding for shows before they launch, NY Times reportsSoftBankis partnering with South Korea's Cosmos Lab and DeltaX to mass produce next-gen data center batteries in Sakai, Japan at a scale of 1 GWh/year from FY27, Bloomberg reportsBoeing'ssuccess hinges on its successor to the 737, Bloomberg says4. MOVERS:Zebra Technologiesrose after providing areport for Q1SI-Bonewas higher after also providing areport for Q1Gitlabfell after announcing aZoomInfowas lower afterand reiterating its FY26 outlookGoProdeclined after reportingand withdrawing its FY26 guidance5. EARNINGS/GUIDANCE:Sea LimitedreportedBayerprovided areport for Q1Qnity Electronicsalso provided areport for Q1Tencent Musicreported ain Q1 earningsHims & Hers Healthprovidedbut raised its FY26 revenue guidanceINDEXES:The Dow rose 56.09, or 0.11%, to 49,760.56, the Nasdaq lost 185.92, or 0.71%, to 26,088.20, and the S&P 500 declined 11.88, or 0.16%, to 7,400.96.
05/12 10:50
Trump Plans to Reduce Beef Import Tariffs
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly.BEEF IMPORTS:The Trump administration is planning to temporarily reduce tariffs on beef imports as soon as Monday, opening the way to import more beef from overseas as part of a broader effort to address record-high beef prices, people familiar with the matter told's Patrick Thomas and Gavin Bade. Publicly traded meat producers include Hormel Foods, JBS, Pilgrim's Prideand Tyson Foods.FDA CHIEF:President Trump has approved a plan to fire Food and Drug Administration Commissioner Marty Makary, Kristin Brown and Ed O'Keefe of CBS News, citing two sources. The timing of his potential termination remains unknown, CBS adds. Similar reports of Makary's firing emerged on Friday. Biotech stocks that could be impacted by the news include Moderna, Sarepta, Xencor, PTC Therapeutics, Biohaven, Edgewise Therapeutics, Design Therapeutics, Ultragenyx, Dyne Therapeutics, Wave Life Sciences, MeiraGTx, uniQure, Regenxbio, Novavaxand Lexeo Therapeutics.FERTILITY BENEFITS:The U.S. departments of Labor, Health and Human Services, and Treasury last night announced a proposed rule that would create a new category of limited excepted benefits to further expand the ability of employers to offer fertility benefits. The agencies stated, "This proposal addresses employers' sparse coverage of fertility-related treatments for the American worker and increases benefit options by easing statutory and regulatory burdens to make IVF and other fertility treatments more affordable. Though most workers of reproductive age receive healthcare coverage through their jobs, the majority do not have robust fertility coverage." The proposed rule would establish a new category of limited excepted benefits. Excepted benefits are generally exempt from the market reforms under the Affordable Care Act and certain other federal health care coverage laws. Stocks with exposure to the fertility space include Progynyand INVO Fertility.VACCINE INQUIRY:Health Secretary Robert F. Kennedy Jr. has said little publicly about vaccines in recent months, at the behest of a White House worried that his unpopular stance will hurt Republicans in November's midterm elections. But he has not abandoned his quest for evidence that they are unsafe, The New York Times' Christina Jewett and Sheryl Gay Stolberg. Working behind the scenes, Kennedy is spearheading an intense push, across health agencies under his purview, for government scientists and federal data contractors to examine his long-held theory that vaccines are helping to fuel an epidemic of chronic disease, according to multiple people familiar with the effort. Publicly traded companies that make vaccines and drugs include Moderna, Pfizer, BioNTech, Novavax, AstraZeneca, Bristol Myers, Eli Lilly, GSK, Johnson & Johnson, Merck, Novartis, Roche, and Sanofi.NEW YORK TIMES:In a post on Truth Social, President Donald Trump, "The Failing New York Times, which is one of the worst newspapers anywhere in the World, and is losing subscribers on an hourly basis, is now at it again. Just like they covered my Landslide 2024 Presidential Election Victory inaccurately, and without shame, constantly making major mistakes and incorrect predictions at every path along the way, they are now trying to justify Obama and Biden's expensively botched attempt at fixing the long broken, unsightly, and unsanitary Reflecting Pool that NOW sits majestically between the Washington Monument and the Lincoln Memorial. They squandered at least 55 Million Dollars haplessly trying, with no chance of success, to get the Reflecting Pool to work. Instead, they made it worse, keeping it closed for years, and ending up with a leaking, smelling, ode to both of their failed Administrations. It was an embarrassment to Washington, D.C., and to our Country, itself. Despite the vast sums of money spent, they never got the pool to work, and cosmetically it was a total mess for all to see. Now, along comes "TRUMP," who is asked by many patriots if I can fix it. The answer is a resounding, YES, and for a "tiny" fraction of the cost! I worked with our now strong Department of the Interior and explained to them that we should view this as a highly sophisticated swimming pool, not the leaking, dilapidated facade, joints and all, of a building. Instead of taking 4 years to build, at a cost, granite pavers and all, of 400 Million Dollars, we could construct a far superior Reflecting Pool for 5 or 6 Million Dollars, and could complete the project in 2 weeks rather than 4 years. What a difference in time and money, and for a far superior end result! This is not just a paint job, like lowlife "reporter," David Fahrenthold, of theso inaccurately and maliciously stated, it is a deeply complicated work of smart and beautiful construction. It won't leak, it will shine, and be the pride of Washington D.C. for decades to come. I saved more than 390 Million Dollars, and 4 years of no "mess," and was, of course, given no credit by the biased New York Times. Also, I didn't give out the contract, "Interior" did, to a contractor I did not know, and have never used before. Thank you for your attention to this matter!"

PTCT Monitor News

PTC Therapeutics Reports Record Q1 2026 Earnings with Raised Guidance

May 08 2026

PTC Therapeutics and Novartis Share Votoplam Study Progress

Apr 29 2026

Palo Alto Investors Boosts Stake in PTC Therapeutics

Mar 09 2026

PTC Therapeutics stock declines amid market stability

Dec 03 2025

PTC Therapeutics Inc Crosses Down 5-Day SMA Amid Insider Selling

Dec 01 2025

PTC Therapeutics R&D Day Announcement

Nov 26 2025

PTC Therapeutics Reaches 52-Week High Amid Mixed Market Signals

Nov 25 2025

PTCT Earnings Analysis

No Data

No Data

People Also Watch